Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Alterations of adiponectin in the course of inflammation and severe sepsis.

Behnes M, Brueckmann M, Lang S, Putensen C, Saur J, Borggrefe M, Hoffmann U.

Shock. 2012 Aug;38(3):243-8. doi: 10.1097/SHK.0b013e318261e0dc.

PMID:
22744305
2.

Alterations of leptin in the course of inflammation and severe sepsis.

Behnes M, Brueckmann M, Lang S, Putensen C, Saur J, Borggrefe M, Hoffmann U.

BMC Infect Dis. 2012 Sep 14;12:217. doi: 10.1186/1471-2334-12-217.

3.

Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.

Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F.

Crit Care Med. 2007 Jan;35(1):69-75.

PMID:
17133181
4.

Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.

De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL.

Crit Care Med. 2006 Jul;34(7):1918-24.

PMID:
16715034
5.

Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alpha (activated).

Yan SB, Brandt JT, Correll NL, Um SL, Bourdage JS.

J Thromb Haemost. 2009 Nov;7(11):1787-94. doi: 10.1111/j.1538-7836.2009.03601.x.

6.

Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-α activated: a pilot study.

Lavaux T, Bilbault P, Launoy A, Gaub MP, Oudet P, Schneider F.

Crit Care. 2010;14(5):R163. doi: 10.1186/cc9252. Epub 2010 Sep 8.

7.

Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?

Ahishakiye D, Lorent S, De Backer D, Gottignies P, Vincent JL.

J Crit Care. 2009 Dec;24(4):590-4. doi: 10.1016/j.jcrc.2009.03.009. Epub 2009 Jul 3.

PMID:
19577419
8.

Drotrecogin alfa (activated) treatment of older patients with severe sepsis.

Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR.

Clin Infect Dis. 2003 Jul 15;37(2):187-95. Epub 2003 Jul 8.

PMID:
12856210
9.

Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha.

Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R, Considine RV.

Obes Res. 2005 Apr;13(4):662-9.

10.

How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Kalil AC, Sun J.

Intensive Care Med. 2008 Oct;34(10):1804-11. doi: 10.1007/s00134-008-1159-8. Epub 2008 May 27.

PMID:
18504550
11.

Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.

Dalton HJ, Carcillo JA, Woodward DB, Short MA, Williams MD.

Pediatr Crit Care Med. 2012 Nov;13(6):639-45. doi: 10.1097/PCC.0b013e318250ad48. Erratum in: Pediatr Crit Care Med. 2013 Feb;14(2):237.

PMID:
22791090
12.

β-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α.

Kameji H, Mochizuki K, Miyoshi N, Goda T.

Nutrition. 2010 Nov-Dec;26(11-12):1151-6. doi: 10.1016/j.nut.2009.09.006. Epub 2010 Jan 25.

PMID:
20097535
13.

[Expression of TSG-6 gene during 3T3-L1 preadipocyte differentiation and regulative role of tumor necrosis factor-alpha].

Guo XR, Ding SL, Pan XQ, Gong HX, Fei L, Ni YH, Chen RH.

Zhonghua Er Ke Za Zhi. 2004 May;42(5):344-7. Chinese.

PMID:
15189690
14.

Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis.

Behnes M, Brueckmann M, Liebe V, Liebetrau C, Lang S, Putensen C, Borggrefe M, Hoffmann U.

J Crit Care. 2008 Dec;23(4):537-41. doi: 10.1016/j.jcrc.2008.09.002.

PMID:
19056019
15.
16.

90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.

Decruyenaere J, De Backer D, Spapen H, Laterre PF, Raemaekers J, Rogiers P, Trine H, Sartral M, Haentjens T, Wagner T.

Acta Clin Belg. 2009 Jan-Feb;64(1):16-22.

PMID:
19317237
17.

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.

Crit Care Med. 2005 Oct;33(10):2266-77.

PMID:
16215381
19.

Drotrecogin alpha (activated): the treatment for severe sepsis?

Vincent JL.

Expert Opin Biol Ther. 2007 Nov;7(11):1763-77. Review.

PMID:
17961098
20.

The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.

Berkman S, Weimert NA, Taber DJ, Baillie GM, Lin A, Baliga P, Chavin KD.

Transpl Infect Dis. 2009 Jun;11(3):269-76. doi: 10.1111/j.1399-3062.2009.00393.x. Epub 2009 Apr 20.

PMID:
19392728

Supplemental Content

Support Center